Researcher Spotlight: Alexandre Vinaud Hirayama, MD Fred Hutchinson Cancer Research Center Chimeric antigen receptor (CAR) T cell therapy is a typeof immunotherapy that genetically modifies a patient’simmune cells to recognize and kill tumor cells. “CAR T cell therapy has shown…
Researcher Spotlight: Rui Guo, PhD Brigham and Women’s Hospital, Harvard Medical School Epstein-Barr virus (EBV) was the first virus found to causeBurkitt lymphoma, a rare and aggressive form of non-Hodgkin lymphoma (NHL). The virus shuts down nearlyall its genes in…
Researcher Spotlight: Edmond Feris, PhD Dartmouth-Hitchcock Norris Cotton Cancer Center Some of the most critical oncogenes responsible fortumor formation in humans are transcription factors. Dr.Feris’ LRF research project focuses on the study of howtranscriptional dysregulation can lead to carcinogenesis(the process…
Researcher Spotlight: Lydie Debaize, PhD Dana-Farber Cancer Institute Most patients treated for mantle cell lymphoma (MCL)achieve complete remission. Nevertheless, a significantnumber of patients will eventually relapse due to theregrowing of rare cancer cells remaining in the bodyafter treatment, which is known…
Researcher Spotlight: Kathleen Dixon, PhD University of Minnesota Twin Cities The pioneer monoclonal antibody therapy rituximab(Rituxan) has revolutionized the treatment of B-cell lymphomas. However, patient response to rituximab varies based on numerous factors, including the affinity with which immune cells…
Researcher Spotlight: Elena Battistello, PhD New York University School of Medicine Peripheral T-cell lymphoma (PTCL) is an aggressive type of non-Hodgkin lymphoma (NHL) derived from the malignant transformation of blood cells called T-lymphocytes. Currently, patients diagnosed with PTCL have limited…
Researcher Spotlight: Marco Ruella, MD Perelman School of Medicine, University of Pennsylvania Chimeric antigen receptor (CAR) T cell therapy has been very successful in certain cancers, such as B-cell leukemia and lymphoma. However, the needle has not moved for most…
Researcher Spotlight: Reid Merryman, MD, MS Dana-FArber Cancer Institute Classical Hodgkin lymphoma (cHL) tumor cells have developed several ways to avoid detection and destruction by the immune system, including expression of immune checkpoint proteins on their surface to shield them…
Researcher Spotlight: Xu Cao, PhD City of Hope and Beckman Research Institute Many types of non-Hodgkin lymphoma (NHL) remain incurable due to its intrinsic genomic instability facilitating the escape from cytotoxic or targeted therapies. “Recent breakthroughs in understanding macrophage-mediated immune…
Researcher Spotlight: Natalie Grover, MD The University of North Carolina at Chapel Hill Although a majority of patients with Hodgkin lymphoma (HL) are cured with first-line therapy; about 15 percent of those patients experience primary refractory disease or relapse after…